Literature DB >> 1977370

A prospective, multicenter study of patients' refusal of antipsychotic medication.

S K Hoge1, P S Appelbaum, T Lawlor, J C Beck, R Litman, A Greer, T G Gutheil, E Kaplan.   

Abstract

Refusal of treatment with antipsychotic medication was studied prospectively in a sample of 1434 psychiatric patients admitted to four acute inpatient units in state-operated mental health facilities in Massachusetts during a 6-month period. Compared with a control group of patients who accepted prescribed antipsychotic treatment, the 103 patients who refused were older, of a higher social class, and less likely to have been prescribed antiparkinsonian medications. On admission, prior to refusal of medication, patients who refused were found to have significantly higher Brief Psychiatric Rating Scale scores than compliant patients and more negative attitudes regarding their hospitalization and past, present, and future treatment. Treatment refusal had negative effects on the hospital milieu and on the patient; refusers were more likely to require seclusion or restraint and had longer hospitalizations than treatment acceptors. Most refusal episodes ended with voluntary acceptance of treatment. In 23% of cases medications were discontinued. Only 18% of the sample reached formal, judicial review, and in every case that did, involuntary treatment was ordered. The policy implications of these findings are discussed.

Entities:  

Keywords:  Analytical Approach; Empirical Approach; Mental Health Therapies; Professional Patient Relationship

Mesh:

Substances:

Year:  1990        PMID: 1977370     DOI: 10.1001/archpsyc.1990.01810220065008

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  12 in total

1.  Compliance therapy in psychotic patients: randomised controlled trial.

Authors:  R Kemp; P Hayward; G Applewhaite; B Everitt; A David
Journal:  BMJ       Date:  1996-02-10

Review 2.  Quetiapine: a review of its safety in the management of schizophrenia.

Authors:  V Dev; J Raniwalla
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

3.  Frequency of Extrapyramidal Adverse Reactions in Schizophrenic Outpatients Treated with Risperidone, Olanzapine, Quetiapine or Haloperidol : Results of the EIRE Study.

Authors:  Julio Bobes; J Rejas; M Garcia-Garcia; F Rico-Villademoros; M P García-Portilla; M Madrigal; G Hernández
Journal:  Clin Drug Investig       Date:  2002-09       Impact factor: 2.859

4.  Adherence to medication regimens and participation in dual-focus self-help groups.

Authors:  Stephen Magura; Alexandre B Laudet; Daneyal Mahmood; Andrew Rosenblum; Edward Knight
Journal:  Psychiatr Serv       Date:  2002-03       Impact factor: 3.084

Review 5.  Treatment refractory schizophrenia: how should we proceed?

Authors:  Z A Sharif
Journal:  Psychiatr Q       Date:  1998

6.  Demographic factors associated with extreme non-compliance in schizophrenia.

Authors:  W Sellwood; N Tarrier
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1994-07       Impact factor: 4.328

7.  Factors associated with medication adherence among psychiatric outpatients at substance abuse risk.

Authors:  Stephen Magura; Andrew Rosenblum; Chunki Fong
Journal:  Open Addict J       Date:  2011-11-11

8.  Lost in the shuffle: the influence of patient classification scheme on views about the relationship between refusal of medication and involvement in important hospital-based outcomes.

Authors:  P C Panzano; W V Rubin
Journal:  Psychiatr Q       Date:  1995

9.  Risk factors for medication non-adherence among psychiatric patients with substance misuse histories.

Authors:  Stephen Magura; Pedro F Mateu; Andrew Rosenblum; Harlan Matusow; Chunki Fong
Journal:  Ment Health Subst Use       Date:  2014-11

10.  Attitude of young psychiatrists toward coercive measures in psychiatry: a case vignette study in Japan.

Authors:  Masaru Tateno; Kanna Sugiura; Kumi Uehara; Daisuke Fujisawa; Yueren Zhao; Naoki Hashimoto; Hidehiko Takahashi; Naofumi Yoshida; Takahiro Kato; Wakako Nakano; Yosuke Wake; Tomohiro Shirasaka; Seiju Kobayashi; Soichiro Sato
Journal:  Int J Ment Health Syst       Date:  2009-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.